靶向测序分析治疗后血浆EB病毒DNA可改善鼻咽癌风险分层
本研究对769例IIB-IVB期鼻咽癌患者在放疗后6-8周采集血浆,采用靶向测序检测EBV DNA。测序法(含定量与片段大小分析)对局部和远处复发的预测性能优于PCR法,以测序推算的血浆EBV DNA占比0.01%为界值,局部和远处复发敏感度分别为88.5%和97.1%,阴性预测值分别为99.1%和99.4%。
要点
- PCR法(界值为可检测到任何水平EBV DNA)预测局部和远处复发的敏感度分别为42.3%和85.3%。
- 测序法以EBV DNA占比0.01%为界值,局部和远处复发敏感度分别为88.5%和97.1%。
- PCR未检出EBV DNA的患者中,测序可进一步区分出5年无进展生存接近90%的亚组。
核心结论
- 采用测序分析治疗后血浆EBV DNA可增强鼻咽癌的预后判断。
- 测序法对局部和远处复发的预测性能均优于PCR法。
研究设计与样本
- 研究纳入769例IIB-IVB期鼻咽癌患者,在放疗后6-8周采集血浆样本。
- 采用靶向测序检测血浆EBV DNA,分析包括定量和片段大小分析。
主要发现
- PCR法(界值为可检测到任何水平EBV DNA)预测局部复发的敏感度为42.3%,预测远处复发的敏感度为85.3%。
- 测序法以血浆EBV DNA占比0.01%为界值,预测局部复发的敏感度为88.5%,阴性预测值为99.1%。
- 测序法以血浆EBV DNA占比0.01%为界值,预测远处复发的敏感度为97.1%,阴性预测值为99.4%。
- PCR未检出EBV DNA的患者中,测序可依据血浆EBV DNA占比进一步区分出5年无进展生存接近90%的亚组。
- 多因素分析中,基于测序的血浆EBV DNA定量水平是预测总生存和无进展生存的独立预后因素,风险比最高。
关键数值与推荐
- PCR法界值为可检测到任何水平血浆EBV DNA。
- 测序法界值为测序推算的血浆EBV DNA占比0.01%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Quantitative measurement of plasma Epstein-Barr virus (EBV) DNA by real-time PCR at the end of primary treatment is a robust prognostic marker for nasopharyngeal carcinoma (NPC) patients. However, up to 40% of patients who would later develop disease recurrence had undetectable post-treatment plasma EBV DNA. Targeted sequencing for the entire EBV genome potentially allows a more comprehensive and unbiased detection of plasma EBV DNA and enables the use of other parameters such as fragment size as biomarkers. Hence, we explored if plasma EBV DNA sequencing might allow more accurate prognostication of NPC patients. PATIENTS AND METHODS: Plasma samples collected from 769 patients with stage IIB-IVB NPC at 6-8 weeks after radiotherapy were analysed using targeted sequencing for EBV DNA. RESULTS: The sensitivities of the PCR-based analysis, at a cut-off of any detectable levels of plasma EBV DNA, for prediction of local and distant recurrences were 42.3% and 85.3%, respectively. The sequencing-based analysis (involving quantitation and size profiling) achieved better performance for both local and distant recurrences than PCR. Using a cut-off of the proportion of plasma EBV DNA deduced by sequencing at 0.01%, the sensitivities of the sequencing-based analysis for local and distant recurrences were 88.5% and 97.1%, with the resultant negative predictive values of 99.1% and 99.4%, respectively. Among patients with undetectable EBV DNA on quantitative PCR, sequencing could further define a subgroup that enjoyed superior survival outcomes based on the proportion of plasma EBV DNA, with a 5-year progression-free survival (PFS) approaching 90%. On multivariate analysis, sequencing-based quantitative level of plasma EBV DNA was the independent prognostic factor with the highest hazard ratio for prediction of overall survival and PFS. CONCLUSION: NPC prognostication using post-treatment plasma EBV DNA could be enhanced through sequencing.
引用
- Chan DCT, Lam WKJ, Hui EP, et al. Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in post-treatment plasma. Ann Oncol. 2022. PMID: 35491007. doi:10.1016/j.annonc.2022.04.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。